Cellectis (CLLS) filed a registration statement with the US Securities and Exchange Commission on Wednesday for the potential resale of up to 44 million ordinary shares, including in the form of American Depository Shares, by AstraZeneca Holdings from time to time.
Cellectis said it will not receive any proceeds from the sale.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.